Topical Tranexamic Acid for Epistaxis
Yes, tranexamic acid can be administered intranasally for epistaxis, and the 2020 American Academy of Otolaryngology guidelines specifically recognize topical TXA as an inexpensive antifibrinolytic agent used to control acute nosebleeds, though they note that additional study is needed to fully understand its indications and efficacy 1.
Critical Caveat: FDA Labeling vs. Off-Label Use
The FDA label for tranexamic acid injection explicitly states it is for intravenous use only and warns that serious adverse reactions including seizures and cardiac arrhythmias have occurred with incorrect routes of administration 2. Intranasal application represents off-label use - the drug is not FDA-approved for this route or indication.
Method of Administration Matters Significantly
Use TXA-saturated gauze or pledgets, NOT atomized spray. The most recent 2026 meta-analysis demonstrates that delivery method is a critical moderator of success 3:
- TXA-saturated gauze/pledgets: Robust, consistent benefit (OR 2.98)
- Atomized delivery: Inconsistent results (OR 0.29)
This finding explains much of the heterogeneity in prior studies and the conflicting results between trials.
Evidence Quality and Recommendations
Supporting Evidence:
2026 meta-analysis (18 studies, 2,760 patients) shows topical TXA significantly improves outcomes when properly administered 3:
- 2.5× higher odds of bleeding cessation within 10 minutes
- 58% reduction in early rebleeding (OR 0.42)
- 55% reduction in late rebleeding (OR 0.45)
- 5.5× more likely to be discharged within 2 hours
- Mean time to hemostasis reduced by 4.68 minutes
2022 Iranian RCT (240 patients) found TXA reduced need for anterior nasal packing from 64.2% to 50.0% (OR 0.56) and reduced 24-hour rebleeding from 30% to 15% (OR 0.41) 4
2024 dose-finding study suggests 1000 mg is superior to 500 mg, with 2.9× less bleeding at 5 minutes and 4.3× less rebleeding 5
Contradictory Evidence:
- 2021 UK multicenter RCT (496 patients, 26 EDs) found no benefit of topical TXA over placebo when applied on cotton wool dental rolls (43.7% vs 41.3% needed packing, p=0.59) 6
The divergence likely reflects application technique - the negative UK study may have used suboptimal contact time or saturation compared to positive studies using pledgets with prolonged mucosal contact.
Practical Application Protocol
For anterior epistaxis uncontrolled by simple measures:
- Prepare TXA-soaked pledgets: Use 1000 mg tranexamic acid (10 mL of 100 mg/mL solution) to saturate cotton pledgets or gauze
- Add vasoconstrictor: Combine with topical phenylephrine or oxymetazoline and lidocaine for anesthesia
- Insert pledgets: Place directly against bleeding site in nostril
- Duration: Leave in place for 15 minutes minimum
- Reassess: If bleeding persists, proceed to cautery or anterior nasal packing per standard protocols
Clinical Context from Guidelines
The AAO-HNS guidelines position TXA within a treatment algorithm that includes 1:
- Initial vasoconstrictor application
- Cautery for identified bleeding sites (preferred when feasible)
- Nasal packing as fallback
- TXA as adjunctive therapy, particularly useful in patients on antiplatelet agents
The guidelines acknowledge the evidence is "moderate quality" with most high-quality studies from Iran, and explicitly state additional research is needed given newer endoscopic techniques 1.
Key Pitfalls to Avoid
- Never administer IV tranexamic acid intrathecally or into neuraxial spaces - this causes seizures and cardiac arrhythmias 2
- Avoid atomized/spray delivery - use saturated pledgets for consistent effect 3
- Don't use in patients with active intravascular clotting - TXA is antifibrinolytic and increases thrombotic risk 2
- Avoid in patients on pro-thrombotic medications (Factor IX concentrates, hormonal contraceptives) without careful risk assessment 2
Bottom Line
Topical intranasal TXA via saturated pledgets is a reasonable adjunctive treatment for anterior epistaxis, particularly in patients on antiplatelet therapy or when trying to avoid nasal packing. Use 1000 mg with vasoconstrictor, applied for at least 15 minutes. This represents off-label use of an IV medication, so document appropriately and be prepared to escalate to standard therapies (cautery, packing) if ineffective.